Navigation Links
Enrollment Begins on Human PK Study for Medidur(TM) FA
Date:8/22/2007

FA in the eye after insertion and drug levels in the anterior chamber."

Alimera Sciences and pSivida Limited have a worldwide agreement to co-develop and market the Medidur insert for the use of FA to treat DME. The agreement also includes the option to identify other compounds for ophthalmic diseases, potentially resulting in three additional products with the Medidur insert.

"The open label PK study that has begun is designed to provide additional pharmacokinetic, safety and efficacy data next year," said Dr Paul Ashton, PhD, Managing Director of pSivida Limited. "Additionally, by determining anterior chamber drug levels, we will gain important knowledge related to one of the key attributes of the Medidur technology, namely minimizing corticosteroid levels in the front of the eye."

About Alimera Sciences Inc.

Alimera Sciences Inc., a venture backed company, specializes in the development and commercialization of prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences' products are focused on improving the delivery of therapeutic agents to enhance patient's lives and to strengthen physicians' ability to manage ocular conditions. Alimera is currently conducting a 900-patient Phase III clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the treatment of diabetic macular edema. For more information, please visit http://www.alimerasciences.com.

About pSivida Limited

pSivida is a global drug delivery company committed to the biomedical sector. Retisert(R) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(R). pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Me
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. Testing for Human Papillomavirus
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
7. Apollos human proteins boost stem cell research
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... prospects for leading ophthalmic drug companies  What ... pharma ophthalmic industry ? Visiongain,s brand new report ... opportunities and prospects there. Our 242-page report ... lucrative areas in the industry and the future market ...
(Date:3/27/2015)... Calif. , March 27, 2015 The ... life of myeloma patients while working toward prevention and ... (D-NY) for introducing a federal resolution (H. Res. ... March 2015 as "National Multiple Myeloma Awareness Month." ... with myeloma worldwide, and more than 110,000 new cases ...
(Date:3/27/2015)... 2015 RnRMarketResearch.com adds "Visceral ... research report of 52 pages with latest updates, ... library. The report "Visceral Pain - Pipeline Review, ... development for Visceral Pain, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... June 29 Noting that only about 200 of the nearly 7,000 ... today called for a Food and Drug Administration (FDA) statement of policy on regulation ... , NORD also urged ... of medicines for rare disorders. , , ...
... , DAYTON and CINCINNATI, Ohio , June 29 ... with Stipkala LLC, was an invited speaker and panel discussion participant at ... in Dayton, Ohio June 16-19, 2010 .  The 2010 ... new technologies in addition to traditional chemical disciplines.   , ...
Cached Medicine Technology:NORD Calls for Statement of Policy on Orphan Drug Development 2Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:3/30/2015)... Considered to be the best assessment tool for ... community, this next generation of the IT Audit ... data and frameworks with virtually endless possibilities. These new ... logic features are a technological force to be reckoned ... “The IT Audit Machine is just one of the ...
(Date:3/30/2015)... 2015 A new recruitment site has ... for their next career move. , Millions of new ... for those with skills in the booming data and ... is a jobs aggregator, pulling in opportunities from both ... them individually to help candidates find suitable big data ...
(Date:3/30/2015)... March 30, 2015 TherapySites, ... for mental health professionals, announced today its affiliation ... TherapySites to extend their online marketing solutions to ... , "As we continue to see advancements in ... the Internet effectively in order to succeed,” said ...
(Date:3/30/2015)... Developing new treatments for Diabetes Type 2 ... models that recapitulate only some subset of the specific ... , A company that specializes in developing and manufacturing ... has created iPSC-derived cardiomyocytes (heart muscle cells), which have ... vitro models of Diabetes Type 2. The development process ...
(Date:3/30/2015)... March 30, 2015 Bunion Bootie ... Buy them for family members, friends...and yourself and save. For ... can save an additional 10%, on top of discounts already ... code "EasterPR" at checkout. The more Bunion Booties purchased, the ... spacers, and bunion pads, Bunion Bootie can be worn comfortably ...
Breaking Medicine News(10 mins):Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:New Global Job Site Launched for Big Data and Analytics Job Seekers 2Health News:TherapySites (Websites for Therapists) Partners with BehaveNet 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2
... primates points to possible weapon against human infection with ... Researchers have successfully tested several Ebola vaccines in monkeys ... vaccine for one of the world,s deadliest diseases. ... overlooked. We are seeing more and more naturally occurring ...
... The Palace was the backdrop,for technology,s royalty last ... "Best in Show" at the 2008 NJ Venture Conference., ... Succeed" and,Switch2Health of New Brunswick took the prize for ... crowd of more than 500 entrepreneurs,and investors looking for ...
... and Chapel Hill, N.C. March 31, 2008 - ... Journal of Medicine, which concluded that lung transplants were ... the latest issue of Pediatric Transplantation refute the conclusions ... flawed. , According to two rebuttals published in the ...
... MIAMI, March 31 According to the World ... blacks, but,many Latinos and a few elderly Whites ... total incurable Glaucoma-Blindness,("White-Canes"). Most lack the opportunity to ... them of all their sight. Dr. Robert,Welsh, a ...
... on ... NEW YORK, March 31 For expectant parents, choosing ... significant decision. But,there are many things that go on behind ... properly in order to ensure a,positive patient experience and a ...
... Lowering the blood pressure of elderly patients could cut ... of cardiovascular events by a third, according to a ... American College of Cardiology in Chicago and published simultaneously ... 3,845 patient Hypertension in the Very Elderly Trial (HYVET), ...
Cached Medicine News:Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 3Health News:Lung transplants not dangerous for children with cystic fibrosis, after all 2Health News:New Welsh 'Self-Test' to Cure Glaucoma, the Leading Cause of Preventable Blindness 2Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 3
LB Agar plates with 10mM Magnesium Sulfate....
1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride, 7.5% Glycerol....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
... Molecular Biology Buffers are ready-to-use solutions ideal ... applications. Each reagent is prepared with 18 ... filter, and filled into sterile bottles., ... control standards to ensure lot-to-lot consistency. ...
Medicine Products: